Phase 3 trial results promising for antibody drug treating HER2 breast cancer type

AstraZeneca and Daiichi Sankyo’s  Enhertu breast cancer drug significantly helped patients with HER2-low metastatic breast cancer in its phase 3 clinical trial, AstraZeneca said Feb. 21.